(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.01%) $0.927
(0.19%) $10.86
(0.07%) $0.793
(-0.32%) $92.28
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
Today's Volume | 14 547.00 |
Average Volume | 52 611.00 |
Market Cap | 144.14M |
EPS | $0 ( 2024-03-07 ) |
Next earnings date | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.970 |
ATR14 | $0.00800 (1.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.88 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. Correlation
10 Most Positive Correlations | |
---|---|
PLPC | 0.902 |
GPOR | 0.891 |
MCAA | 0.89 |
ENTF | 0.887 |
MLAI | 0.886 |
PPYA | 0.884 |
AHRN | 0.883 |
FRSG | 0.882 |
ACQR | 0.88 |
FTAA | 0.88 |
10 Most Negative Correlations | |
---|---|
INCY | -0.916 |
SRTS | -0.904 |
FARO | -0.897 |
BXRX | -0.896 |
NWL | -0.895 |
CDXS | -0.892 |
NURO | -0.888 |
AYTU | -0.888 |
RCKY | -0.886 |
SBAC | -0.88 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
DBV Technologies S.A. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $4.50M (0.00 %) |
EPS: | $-0.380 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $13.57M (0.00 %) |
EPS: | $-0.0581 |
Q3 | 2023 |
Revenue: | $2.40M |
Gross Profit: | $1.94M (81.02 %) |
EPS: | $-0.170 |
Q2 | 2023 |
Revenue: | $2.29M |
Gross Profit: | $-2.69M (-117.57 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators